Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NICOX

Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
From NICOX
Via GlobeNewswire
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
From NICOX
Via GlobeNewswire
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
From NICOX
Via GlobeNewswire
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
From NICOX
Via GlobeNewswire
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
From NICOX
Via GlobeNewswire
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
From NICOX
Via GlobeNewswire
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
From NICOX
Via GlobeNewswire
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
From NICOX
Via GlobeNewswire
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®
From NICOX
Via GlobeNewswire
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
From NICOX
Via GlobeNewswire
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
From NICOX
Via GlobeNewswire
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
From NICOX
Via GlobeNewswire
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
From NICOX
Via GlobeNewswire
Nicox Provides Second Quarter 2023 Financial and Business Highlights
From NICOX
Via GlobeNewswire
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
From NICOX
Via GlobeNewswire
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
From NICOX
Via GlobeNewswire
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China
From NICOX
Via GlobeNewswire
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023
From NICOX
Via GlobeNewswire
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
From NICOX
Via GlobeNewswire
Nicox Provides First Quarter 2023 Financial and Business Highlights
From NICOX
Via GlobeNewswire
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China
From NICOX
Via GlobeNewswire
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress
From NICOX
Via GlobeNewswire
Nicox Reports 2022 Financial Results and Updates Key Future Milestones
From NICOX
Via GlobeNewswire
Nicox to Present at Upcoming Scientific Conferences
From NICOX
Via GlobeNewswire
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023
From NICOX
Via GlobeNewswire
Nicox Provides Fourth Quarter 2022 Financial Highlights
From NICOX
Via GlobeNewswire
Nicox Announces Proposed Move to Euronext Growth Paris
From NICOX
Via GlobeNewswire
Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
From NICOX
Via GlobeNewswire
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470
From NICOX
Via GlobeNewswire
Nicox Provides Third Quarter 2022 Financial and Business Highlights
From NICOX
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.